First DSA System of MicroImaging® Receives NMPA Marketing Approval

Shenzhen, China, 4 November 2021 — Soul-ManTM, a Medical X-ray Angiography System jointly developed by MicroImaging (Shenzhen) Medical Equipment Co., Ltd. (MicroImaging®), a subsidiary of MicroPort Scientific Corporation (MicroPort®), and Siemens Healthineers, has received approval for marketing by China’s National Medical Products Administration (NMPA).

Based on digital subtraction angiography (DSA) technology, Soul-ManTM is suitable for angiography, X-ray fluoroscopy, digital radiography, digital subtraction angiography and 3D images during interventional procedures. It features low dose acquisitions, low contrast agent usage, compact design, flexible movements, intelligent human-machine interactions and high-density-resolution images.

Mr. Lei Jiang, Chairman of the Board of MicroImaging®, stated, “The approval of our first product signals MicroImaging®'s entry into the realm of precision medical imaging, as well as our first move towards developing collaborations with primary care facilities. This is a significant step forward in the evolution of MicroImaging®. In the future, MicroImaging® will continue to adhere to MicroPort®’s brand philosophy of, ‘The Patient Always Comes First’, and strive to provide accessible medical solutions for precision diagnosis to benefit patients.”

With the advancement of vascular intervention technology, the demand for DSA is rising rapidly. Over 1,000 DSA units were sold in China in 2019, and the number is expected to exceed 2,000 units by 2024, with a compound annual growth rate of about 14%.

About MicroImaging®

Founded in August 2019, MicroImaging (Shenzhen) Medical Equipment Co., Ltd. (MicroImaging®), a subsidiary of MicroPort Scientific Corporation (00853.HK, MicroPort®), is dedicated to the research and development, production and supply chain integration of medical imaging equipment related to operating and catheterization rooms. MicroImaging® is committed to creating the world’s leading imaging equipment products and platforms, and providing inclusive and accurate diagnosis and treatment programs for hospitals and patients. The product pipelines cover non-invasive imaging systems and minimum invasive imaging systems, employing multi-modalities such as X-ray, nuclear magnetic resonance, ultrasound, near infrared etc.